2016
Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL
Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, Al-Ahmad A, Turakhia MP. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circulation Arrhythmia And Electrophysiology 2016, 9: e003407. PMID: 27307517, PMCID: PMC4911813, DOI: 10.1161/circep.115.003407.Peer-Reviewed Original ResearchConceptsLAA closureLeft atrial appendageQuality-adjusted life yearsPROTECT AFAtrial fibrillationPercutaneous closureWatchman deviceAtrial appendageLife yearsTrial dataWATCHMAN LAA closure devicePROTECT AF trialIncremental cost-effectiveness ratioMajor adverse eventsPrevention of strokeAtrial appendage closureProspective Randomized EvaluationLAA closure deviceLong-term trial resultsQuality-adjusted survivalCost-effectiveness ratioCost-effectiveness resultsMedical anticoagulationAF trialAdverse events
2012
Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation
Solomon MD, Ullal AJ, Hoang DD, Freeman JV, Heidenreich P, Turakhia MP. Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. Journal Of Cardiovascular Medicine 2012, 13: 86-96. PMID: 22193838, DOI: 10.2459/jcm.0b013e32834f23cf.Peer-Reviewed Original ResearchConceptsCost-effectiveness analysisAtrial fibrillationNonpharmacologic therapiesAtrial fibrillation-related strokeVitamin K antagonistsNew pharmacologic therapiesDirect thrombin inhibitorDevice-based therapiesLeft atrial appendageStroke Risk ProfileHealth policy recommendationsPercutaneous ligationStroke prophylaxisK antagonistsStroke preventionPharmacologic therapySurgical ligationAbnormal heart rhythmAntiplatelet agentsProphylaxis strategiesAtrial appendageRight atriumEndovascular implantationInvasive therapySystemic circulation
2010
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Annals Of Internal Medicine 2010, 154: 1-11. PMID: 21041570, DOI: 10.7326/0003-4819-154-1-201101040-00289.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsAtrial FibrillationBenzimidazolesBeta-AlanineCost-Benefit AnalysisDabigatranFibrinolytic AgentsHemorrhageHumansIntracranial HemorrhagesIschemic Attack, TransientMarkov ChainsMyocardial InfarctionQuality-Adjusted Life YearsRisk FactorsSensitivity and SpecificityStrokeWarfarinConceptsHigh-dose dabigatranIncremental cost-effectiveness ratioNonvalvular atrial fibrillationLow-dose dabigatranCost-effectiveness ratioAtrial fibrillationIschemic strokeCost of dabigatranIntracranial hemorrhageClinical trialsOral direct thrombin inhibitorVeterans Affairs Health Services ResearchSingle randomized clinical trialAdjusted-dose warfarinStudies of anticoagulationPatients 65 yearsRE-LY trialDirect thrombin inhibitorRandomized clinical trialsAmerican Heart AssociationQuality-adjusted life expectancyQuality-adjusted survivalBase-case analysisHealth services researchStroke prevention
2009
The ageing athlete: screening prior to vigorous exertion in asymptomatic adults without known cardiovascular disease
Freeman J, Froelicher V, Ashley E. The ageing athlete: screening prior to vigorous exertion in asymptomatic adults without known cardiovascular disease. British Journal Of Sports Medicine 2009, 43: 696. PMID: 19734505, DOI: 10.1136/bjsm.2008.054783.Peer-Reviewed Original ResearchConceptsExercise ECG testingVigorous exercise programRisk factorsObservational studyECG testingCV eventsAsymptomatic patientsAsymptomatic menAsymptomatic adultsExercise programPrognostic valueExercise electrocardiogramCardiovascular diseaseMore CV risk factorsMultiple cardiac risk factorsAsymptomatic healthy womenIncident CV eventsCardiac risk factorsCV risk factorsProspective observational studySimilar prognostic valueExercise ECG testMore conclusive dataRisk factor exposureElderly patients